SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the board considers a compensation package for Musk tied to ambitious goals, including AI and robotaxi milestones, sparking debate about the company's future and valuation. The community is discussing the feasibility of these targets, potential impacts on shareholders, and Tesla's competitive positioning in the evolving EV and robotics landscape. Bullish sentiment is fueled by potential breakout signals, while bears cite concerns about sales, brand image, and reliance on future promises.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as community members rally behind its fair launch and Bitcoin-native foundation, setting it apart from other meme coins. The community emphasizes its strong ties to the Bitcoin network, with some suggesting it could become the leading meme coin of this cycle. Discussions highlight the absence of insiders and VC involvement, promoting it as a truly decentralized and community-driven project.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending as traders discuss potential catalysts, including AI integration and buyout speculation. Chatter on WallStreetBets and Reddit highlights high short interest and potential for a squeeze. Community members are also weighing potential acquisitions and comparing SNAP's valuation to peers.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor ($OPEN) is trending as retail investors rally behind potential catalysts like a new CEO announcement and speculation around future interest rate cuts. Community members are actively discussing potential gamma squeezes, the influence of activist investor Eric Jackson, and celebrity endorsements. Some are drawing comparisons to past meme stock rallies, while others express concern about the company's fundamentals.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as the NFL season approaches, sparking discussions about potential record betting and the impact of recent partnerships. The community is weighing the implications of prediction markets and potential regulatory changes, with some expressing concerns about competition while others see opportunities for expansion. Overall, sentiment appears cautiously optimistic as investors monitor key metrics and upcoming catalysts.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

The crypto community is buzzing about $DOG, a new meme coin on the Bitcoin network, celebrated for its fair launch and community-driven approach. Many see it as the premier meme coin for Bitcoin, drawing comparisons to $SHIB's role on Ethereum and predicting it will overtake $DOGE. Community members are drawn to its organic growth, lack of insider allocation, and strong support base, with some anticipating listings on major exchanges.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is trending as the community discusses its potential breakout and future price predictions, with some expressing excitement and bullish sentiment. Conversations also revolve around the project's use case in identity verification, particularly distinguishing humans from AI bots, and its association with Sam Altman. However, some users remain skeptical due to concerns about dilution, privacy, and the project's overall utility.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's potential S&P 500 inclusion is driving significant interest, with community members actively discussing strategies around call options and anticipating institutional investment. Bullish sentiment is fueled by the expectation of increased visibility and fund allocation, while some traders are wary of a potential 'sell the news' event. Prediction markets and overall growth potential are also being weighed.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

BBIO is trending as community members discuss positive Phase 2 data for their drug encaleret, which showed promise in treating post-surgical hypoparathyroidism, with registrational trials planned for 2026. Bullish sentiment is driven by the drug's potential to capture a significant portion of a multi-billion dollar market and upcoming Phase 3 readouts. Additionally, J.P. Morgan raised its price target, contributing to the stock's upward momentum.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending amid speculation of a potential acquisition by Nestlé following leadership changes and a rumor reported by Swiss media. The community is actively debating the legitimacy of the offer and the potential for a short squeeze, given MCRB's high short interest. Some investors believe a deal is imminent, while others remain skeptical until official news is released.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BeOne Medicines Ltd. - Sponsored ADR  (ONC) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for BeOne Medicines Ltd. - Sponsored ADR  (ONC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock?

Stevanato (STVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

BeOne Medicines Ltd. - Sponsored ADR  (ONC) Surges 4.0%: Is This an Indication of Further Gains?

BeOne Medicines Ltd. - Sponsored ADR  (ONC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Shares of Summit Therapeutics Inc. (SMMT) surged more than 21% on Wednesday and extended gains in after-hours trading, driven by encouraging results from a late-stage cancer drug trial.The company’s sponsor, Akeso, announced that a phase 3 trial evaluating Summit’s drug, ivonescimab, in combination with chemotherapy, met its primary endpoint of progression-free survival in patients with advanced squamous non-small cell lung cancer (NSCLC).Akeso conducted the study across multiple centers in China, comparing the combination against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.An independent data monitoring committee found that the ivonescimab arm demonstrated statistically significant and clinically meaningful improvement.Summit plans to present the full dataset from the trial at a major medical conference later this year.&nbsp;On Stocktwits, sentiment for Summit rose further within 'extremely bullish' levels amid a 507% spike in 24-hour message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SMMT_sentiment_and_message_volume_as_of_April_23_png_a70ccf1959.webp" alt="SMMT sentiment and message volume as of April 23.png" width="1318" height="316"><figcaption>SMMT sentiment and message volume as of April 23. | source: Stocktwits</figcaption></figure>One bullish watcher urged investors to watch out for a "short squeeze up to $40."<stembedurl>https://stocktwits.com/BooEmmy/message/612403946</stembedurl>"The path is rising. And the journey has only just begun," said another.<stembedurl>https://stocktwits.com/Teluride/message/612467520</stembedurl>Summit is enrolling patients in a separate multiregional study pitting the same combination against pembrolizumab (Merck's Keytruda) plus chemo in first-line metastatic NSCLC. Early trial results from China have already shown promising results.The company also boosted investor enthusiasm after joining a clinical trial&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/smmt-retail-chatter-explodes-on-pfizer-trial-pact/chdEqVTRx8">collaboration</a> with Pfizer in February.Summit's stock has surged by over 84% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.

Equity

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.


BeiGene to Present at Upcoming Investor Conferences

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Company will participate in fireside...

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial...

<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio shares</a> surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks&nbsp;while lifting retail sentiment.The clinical-stage immunotherapy company announced a collaboration and supply agreement with BeiGene to conduct a confirmatory Phase 3 clinical trial.&nbsp;The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for patients with advanced or metastatic non-small cell lung cancer who have developed resistance to immune checkpoint inhibitor therapy.According to ImmunityBio, multiple Phase 1 and 2 studies have already shown prolonged overall survival with this combination compared to historical chemotherapy results in similar patients.&nbsp;The upcoming Phase 3 trial, conducted globally across multiple sites, will enroll 462 participants. The primary endpoint is overall survival, while secondary measures include disease control rate, progression-free survival, objective response rate, and safety.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/IBRX_sentiment_and_message_volume_Jan_29_015db24b68.png" alt="IBRX sentiment and message volume Jan 29.png" width="1318" height="324"><figcaption>IBRX sentiment and message volume Jan 29 as of 1:30 pm ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘bullish’ for ImmunityBio on Wednesday, up from ‘neutral’ a day ago, while BeiGene’s sentiment shifted to ‘extremely bullish’ amid a spike in message volume.&nbsp;One user speculated that BeiGene could also become ImmunityBio’s global partner for bladder cancer treatments, suggesting another announcement might follow soon.&nbsp;<stembedurl>https://stocktwits.com/Dmck9/message/601987411</stembedurl>Another post predicted a 150% rally in the coming weeks.<stembedurl>https://stocktwits.com/Terrashae/message/601984996</stembedurl>ImmunityBio has been a closely watched stock among retail traders, with its Stocktwits following growing by nearly 43% in the past year despite a 10% decline in the stock’s price over the same period.&nbsp;Year to date, however, shares are up nearly 28%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism

The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer

BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the appointment of Giancarlo Benelli as...

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.63	--	--	N/A
Q2 '25	$0.32	$0.91	183.43%	BEAT
Q1 '25	-$0.53	$0.00	100.00%	BEAT
Q4 '24	-$1.04	-$1.43	-37.50%	MISSED
Q3 '24	--	-$1.15	--	N/A

ONC
BeiGene Ltd - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ONC News

ONC BeiGene Ltd - ADR